| 25.58 -0.42 (-1.62%) | 09-24 13:20 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 31.29 | 1-year : | 32.63 |
| Resists | First : | 26.79 | Second : | 27.94 |
| Pivot price | 25.97 |
|||
| Supports | First : | 24.93 | Second : | 20.74 |
| MAs | MA(5) : | 25.74 |
MA(20) : | 26.26 |
| MA(100) : | 25.55 |
MA(250) : | 25.06 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 43.7 |
D(3) : | 33.8 |
| RSI | RSI(14): 47.9 |
|||
| 52-week | High : | 27.94 | Low : | 22.26 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ THNR ] has closed above bottom band by 49.6%. Bollinger Bands are 41% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 26.41 - 26.52 | 26.52 - 26.62 |
| Low: | 25.61 - 25.73 | 25.73 - 25.84 |
| Close: | 26.1 - 26.29 | 26.29 - 26.46 |
The Amplify Weight Loss Drug & Treatment ETF (THNR) offers investors a way to access international firms poised to benefit financially from advancements in weight management pharmaceuticals. Its primary objective is to mirror the investment performance (before any fees or expenses) of the VettaFi Weight Loss Drug & Treatment Index.
Tue, 22 Sep 2026
5 Best GLP-1 Stocks for 2026 and How to Invest - The Motley Fool
Mon, 21 Sep 2026
THNR's Weight-Loss Index Swaps Hims & Hers for Gilead - ETF Database
Tue, 21 Jul 2026
THNR ETF Profile: Dividends, Returns (AMEX:THNR) - TradingView
Tue, 07 Jul 2026
Inside THNR: A Leaner Approach to Weight Loss Investing - ETF Database
Thu, 11 Jun 2026
Healthcare ETFs: From Broad Exposure to Big Breakthroughs - ETF Trends
Wed, 10 Jun 2026
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market - theglobeandmail.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|